Entrada Therapeutics (TRDA) Financials

$7.69 -0.55 (-6.67%)

Closing price 04:00 PM Eastern

Extended Trading

$7.70 +0.00 (+0.07%)

As of 04:04 PM Eastern

Annual Income Statements for Entrada Therapeutics

This table shows Entrada Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	66	-6.69	-97
Consolidated Net Income / (Loss)	66	-6.69	-95
Net Income / (Loss) Continuing Operations	66	-6.69	-95
Total Pre-Tax Income	66	12	-95
Total Operating Income	47	-3.16	-97
Total Gross Profit	211	129	0.00
Total Revenue	211	129	0.00
Operating Revenue	211	129	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	164	132	97
Selling, General & Admin Expense	38	32	31
Research & Development Expense	125	100	67
Total Other Income / (Expense), net	19	15	2.63
Other Income / (Expense), net	19	15	2.63
Income Tax Expense	0.86	19	0.00
Basic Earnings per Share	$1.76	($0.20)	($3.02)
Weighted Average Basic Shares Outstanding	37.31M	33.05M	31.29M
Diluted Earnings per Share	$1.68	($0.20)	($3.02)
Weighted Average Diluted Shares Outstanding	39.00M	33.05M	31.29M
Weighted Average Basic & Diluted Shares Outstanding	37.59M	33.60M	33.08M

This table shows Entrada Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	1.21	-14	55	23	-10	36	-26	-6.67	-27	-25
Consolidated Net Income / (Loss)	1.13	-14	55	23	-9.54	35	-26	-6.67	-25	-25
Net Income / (Loss) Continuing Operations	1.13	-14	55	23	-9.54	35	-26	-6.67	-25	-25
Total Pre-Tax Income	-0.74	-16	58	25	9.20	18	-12	-3.12	-25	-25
Total Operating Income	-5.87	-22	53	21	4.91	14	-16	-5.78	-26	-26
Total Gross Profit	37	20	95	59	42	44	18	25	-	0.00
Total Revenue	37	20	95	59	42	44	18	25	-	0.00
Operating Revenue	37	20	95	59	42	44	18	25	-	0.00
Total Operating Expenses	43	41	41	38	37	30	34	31	26	26
Selling, General & Admin Expense	9.86	9.97	9.24	9.40	8.65	7.53	8.17	7.94	9.89	6.98
Research & Development Expense	33	31	32	29	28	22	26	23	16	19
Total Other Income / (Expense), net	5.13	5.77	4.37	4.21	4.29	4.05	4.22	2.66	0.95	0.80
Other Income / (Expense), net	5.13	5.77	4.37	4.21	-	4.05	-	2.66	0.95	0.80
Income Tax Expense	-1.87	-1.86	2.76	1.83	19	-17	14	3.55	-	0.00
Basic Earnings per Share	($0.20)	($0.35)	$1.61	$0.70	($0.28)	$1.07	($0.78)	($0.21)	($0.79)	($0.80)
Weighted Average Basic Shares Outstanding	37.31M	40.63M	34.18M	33.50M	33.05M	33.28M	33.16M	32.37M	31.29M	31.30M
Diluted Earnings per Share	($0.20)	($0.35)	$1.55	$0.68	($0.23)	$1.02	($0.78)	($0.21)	($0.79)	($0.80)
Weighted Average Diluted Shares Outstanding	39.00M	40.63M	35.51M	34.79M	33.05M	34.78M	33.16M	32.37M	31.29M	31.30M
Weighted Average Basic & Diluted Shares Outstanding	37.59M	37.42M	37.20M	33.76M	33.60M	33.37M	33.27M	33.20M	33.08M	31.41M

This table details how cash moves in and out of Entrada Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	34	22	-242
Net Cash From Operating Activities	-42	140	-94
Net Cash From Continuing Operating Activities	-42	140	-94
Net Income / (Loss) Continuing Operations	66	-6.69	-95
Consolidated Net Income / (Loss)	66	-6.69	-95
Depreciation Expense	3.77	2.84	1.90
Amortization Expense	-10	-5.78	0.15
Non-Cash Adjustments To Reconcile Net Income	18	13	18
Changes in Operating Assets and Liabilities, net	-119	136	-19
Net Cash From Investing Activities	-28	-138	-149
Net Cash From Continuing Investing Activities	-28	-138	-149
Purchase of Property, Plant & Equipment	-3.16	-5.61	-2.89
Purchase of Investments	-438	-407	-222
Sale and/or Maturity of Investments	413	274	76
Net Cash From Financing Activities	103	21	0.48
Net Cash From Continuing Financing Activities	103	21	0.48
Issuance of Common Equity	103	21	0.20
Cash Income Taxes Paid	4.62	15	0.00

This table details how cash moves in and out of Entrada Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	23	-107	117	0.83	16	-28	-148	182	-8.15	-38
Net Cash From Operating Activities	-32	-24	40	-26	-4.01	-24	-35	203	-27	-27
Net Cash From Continuing Operating Activities	-32	-24	40	-26	-4.01	-24	-35	203	-27	-27
Net Income / (Loss) Continuing Operations	1.13	-14	55	23	-9.54	35	-26	-6.67	-25	-25
Consolidated Net Income / (Loss)	1.13	-14	55	23	-9.54	35	-26	-6.67	-25	-25
Depreciation Expense	0.99	0.94	0.91	0.93	0.74	0.83	0.73	0.54	0.53	0.52
Amortization Expense	-2.51	-3.21	-2.26	-2.04	-2.00	-1.85	-1.69	-0.24	-0.10	-0.03
Non-Cash Adjustments To Reconcile Net Income	4.70	4.86	4.62	3.73	3.84	3.40	3.12	2.76	11	2.71
Changes in Operating Assets and Liabilities, net	-36	-13	-18	-52	2.95	-62	-11	207	-14	-5.54
Net Cash From Investing Activities	53	-83	-24	26	19	-3.74	-113	-40	19	-10
Net Cash From Continuing Investing Activities	53	-83	-24	26	19	-3.74	-113	-40	19	-10
Purchase of Property, Plant & Equipment	-0.64	-0.64	-1.05	-0.84	-0.98	-1.45	-1.52	-1.67	-0.71	-0.81
Purchase of Investments	-64	-166	-111	-97	-89	-77	-140	-102	-	-39
Sale and/or Maturity of Investments	118	83	87	124	109	75	28	63	20	30
Net Cash From Financing Activities	1.40	-0.01	101	0.21	0.69	0.37	0.44	20	0.36	0.06
Net Cash From Continuing Financing Activities	1.40	-0.01	101	0.21	0.69	0.37	0.44	20	0.36	0.06
Issuance of Common Equity	3.09	-0.39	100	0.00	1.44	-	0.19	19	0.20	-

This table presents Entrada Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	526	469	252
Total Current Assets	440	370	210
Cash & Equivalents	101	68	45
Short-Term Investments	319	284	144
Prepaid Expenses	16	12	21
Other Current Assets	3.68	5.88	0.00
Plant, Property, & Equipment, net	11	11	7.68
Total Noncurrent Assets	75	88	35
Other Noncurrent Operating Assets	75	88	35
Total Liabilities & Shareholders' Equity	526	469	252
Total Liabilities	98	227	40
Total Current Liabilities	39	159	22
Short-Term Debt	7.56	-	8.41
Accounts Payable	4.26	3.28	5.99
Accrued Expenses	13	11	7.58
Current Deferred Revenue	14	132	0.00
Current Deferred & Payable Income Tax Liabilities	0.67	4.02	0.00
Total Noncurrent Liabilities	58	68	18
Noncurrent Deferred Revenue	6.51	7.72	0.00
Other Noncurrent Operating Liabilities	52	60	18
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	429	242	213
Total Preferred & Common Equity	429	242	213
Total Common Equity	429	242	213
Common Stock	558	437	403
Retained Earnings	-129	-195	-188
Accumulated Other Comprehensive Income / (Loss)	-0.04	0.20	-2.06

This table presents Entrada Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	555	582	511	485	494	476	274
Total Current Assets	465	490	414	383	390	434	235
Cash & Equivalents	78	185	68	52	80	228	53
Short-Term Investments	371	284	259	302	297	184	162
Prepaid Expenses	13	12	9.24	24	9.66	16	19
Other Current Assets	2.60	7.67	78	5.03	3.74	6.30	-
Plant, Property, & Equipment, net	11	11	11	11	11	9.39	7.44
Total Noncurrent Assets	78	81	86	91	93	32	32
Other Noncurrent Operating Assets	78	81	86	91	93	32	32
Total Liabilities & Shareholders' Equity	555	582	511	485	494	476	274
Total Liabilities	132	152	241	238	287	246	41
Total Current Liabilities	71	86	174	165	126	148	22
Short-Term Debt	7.74	-	-	-	-	-	-
Accounts Payable	1.29	1.64	2.53	0.75	2.42	6.47	1.34
Accrued Expenses	13	11	8.79	9.60	7.11	12	12
Current Deferred Revenue	46	60	148	148	102	122	-
Current Deferred & Payable Income Tax Liabilities	2.25	4.11	5.86	-	7.36	-	-
Total Noncurrent Liabilities	62	66	68	73	161	98	20
Capital Lease Obligations	54	-	-	-	-	-	-
Noncurrent Deferred Revenue	7.96	10	9.41	11	96	89	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	422	430	269	247	207	230	233
Total Preferred & Common Equity	422	430	269	247	207	230	233
Total Common Equity	422	430	269	247	207	230	233
Common Stock	552	547	441	433	429	425	400
Retained Earnings	-130	-116	-171	-185	-221	-195	-164
Accumulated Other Comprehensive Income / (Loss)	0.97	-0.33	-0.25	-0.50	-1.01	-0.64	-2.75

This table displays calculated financial ratios and metrics derived from Entrada Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	63.38%	0.00%	0.00%
EBITDA Growth	560.67%	109.85%	-84.99%
EBIT Growth	451.47%	112.74%	-84.95%
NOPAT Growth	2,546.62%	102.58%	-90.21%
Net Income Growth	1,081.69%	92.93%	-84.95%
EPS Growth	940.00%	93.38%	62.99%
Operating Cash Flow Growth	-129.73%	249.07%	-84.39%
Free Cash Flow Firm Growth	-155.32%	254.97%	-118.97%
Invested Capital Growth	114.82%	-439.89%	321.32%
Revenue Q/Q Growth	-2.07%	48.01%	0.00%
EBITDA Q/Q Growth	16.32%	126.13%	-7.08%
EBIT Q/Q Growth	15.06%	135.83%	-6.99%
NOPAT Q/Q Growth	11.68%	107.44%	-7.90%
Net Income Q/Q Growth	19.43%	69.29%	-6.99%
EPS Q/Q Growth	1.82%	73.68%	-122.17%
Operating Cash Flow Q/Q Growth	-197.58%	19.99%	-7.77%
Free Cash Flow Firm Q/Q Growth	20.38%	42.17%	0.00%
Invested Capital Q/Q Growth	-52.82%	-2.52%	82.73%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	0.00%
EBITDA Margin	28.58%	7.07%	0.00%
Operating Margin	22.30%	-2.45%	0.00%
EBIT Margin	31.54%	9.34%	0.00%
Profit (Net Income) Margin	31.13%	-5.18%	0.00%
Tax Burden Percent	98.71%	-55.45%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	1.29%	155.45%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	19.56%	-2.94%	-37.01%
Cash Return on Invested Capital (CROIC)	-489.22%	0.00%	-464.48%
Operating Return on Assets (OROA)	13.36%	3.34%	0.00%
Return on Assets (ROA)	13.18%	-1.85%	0.00%
Return on Common Equity (ROCE)	19.56%	-2.94%	-37.01%
Return on Equity Simple (ROE_SIMPLE)	15.31%	-2.76%	-44.51%
Net Operating Profit after Tax (NOPAT)	46	1.75	-68
NOPAT Margin	22.02%	1.36%	0.00%
Net Nonoperating Expense Percent (NNEP)	5.03%	-3.17%	-11.26%
Return On Investment Capital (ROIC_SIMPLE)	10.64%	0.72%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	18.25%	25.03%	0.00%
R&D to Revenue	59.45%	77.42%	0.00%
Operating Expenses to Revenue	77.70%	102.45%	0.00%
Earnings before Interest and Taxes (EBIT)	66	12	-95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	60	9.12	-93
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.51	2.08	2.00
Price to Tangible Book Value (P/TBV)	1.51	2.08	2.00
Price to Revenue (P/Rev)	3.07	3.90	0.00
Price to Earnings (P/E)	9.86	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	10.14%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	14.44	0.00	7.58
Enterprise Value to Revenue (EV/Rev)	1.11	1.17	0.00
Enterprise Value to EBITDA (EV/EBITDA)	3.89	16.62	0.00
Enterprise Value to EBIT (EV/EBIT)	3.53	12.57	0.00
Enterprise Value to NOPAT (EV/NOPAT)	5.05	86.44	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	1.08	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	1.06	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.02	0.00	0.04
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.14	-1.17	-0.92
Leverage Ratio	1.48	1.59	1.09
Compound Leverage Factor	1.48	1.59	1.09
Debt to Total Capital	1.73%	0.00%	3.80%
Short-Term Debt to Total Capital	1.73%	0.00%	3.80%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.27%	100.00%	96.20%
Debt to EBITDA	0.13	0.00	-0.09
Net Debt to EBITDA	-6.85	0.00	1.95
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.16	0.00	-0.12
Net Debt to NOPAT	-8.89	0.00	2.65
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	5.36	1.65	5.06
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	11.15	2.33	9.55
Quick Ratio	10.64	2.22	8.59
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-79	144	-93
Operating Cash Flow to CapEx	-1,315.93%	2,490.26%	-3,248.56%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.42	0.36	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	19.06	13.67	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	16	-110	32
Invested Capital Turnover	-4.52	-3.34	0.00
Increase / (Decrease) in Invested Capital	126	-142	25
Enterprise Value (EV)	235	152	244
Market Capitalization	647	504	425
Book Value per Share	$11.46	$7.26	$6.77
Tangible Book Value per Share	$11.46	$7.26	$6.77
Total Capital	436	242	221
Total Debt	7.56	0.00	8.41
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-412	-352	-180
Capital Expenditures (CapEx)	3.16	5.61	2.89
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-12	-141	7.60
Debt-free Net Working Capital (DFNWC)	408	211	196
Net Working Capital (NWC)	401	211	188
Net Nonoperating Expense (NNE)	-19	8.44	27
Net Nonoperating Obligations (NNO)	-412	-352	-180
Total Depreciation and Amortization (D&A)	-6.25	-2.94	2.05
Debt-free, Cash-free Net Working Capital to Revenue	-5.64%	-109.29%	0.00%
Debt-free Net Working Capital to Revenue	193.62%	163.53%	0.00%
Net Working Capital to Revenue	190.03%	163.53%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$1.76	($0.20)	($3.02)
Adjusted Weighted Average Basic Shares Outstanding	37.31M	33.05M	31.29M
Adjusted Diluted Earnings per Share	$1.68	($0.20)	($3.02)
Adjusted Weighted Average Diluted Shares Outstanding	39.00M	33.05M	31.29M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.59M	33.60M	33.08M
Normalized Net Operating Profit after Tax (NOPAT)	46	-2.21	-68
Normalized NOPAT Margin	22.02%	-1.72%	0.00%
Pre Tax Income Margin	31.54%	9.34%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Entrada Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-10.63%	-55.25%	421.16%	134.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-161.89%	-206.59%	426.99%	959.31%	115.05%	169.14%	23.53%	86.66%	-33.87%	-74.50%
EBIT Growth	-115.07%	-187.98%	454.56%	910.98%	119.92%	171.86%	29.68%	85.59%	-33.51%	-74.20%
NOPAT Growth	19.32%	-155.11%	545.89%	584.10%	71.57%	251.52%	30.88%	73.91%	-38.56%	-80.56%
Net Income Growth	111.85%	-139.57%	312.25%	452.05%	61.25%	241.07%	-11.86%	69.20%	-33.51%	-74.20%
EPS Growth	13.04%	-134.31%	298.72%	423.81%	70.89%	227.50%	-5.41%	69.57%	-104.98%	91.82%
Operating Cash Flow Growth	-687.57%	0.92%	213.51%	-112.55%	85.30%	10.88%	-94.85%	1,068.98%	-32.92%	-95.25%
Free Cash Flow Firm Growth	-195.02%	-202.91%	-146.51%	-154.52%	421.81%	559.75%	701.78%	760.33%	0.00%	-158.80%
Invested Capital Growth	114.82%	132.19%	76.56%	68.11%	-439.89%	-705.82%	-1,541.50%	-1,449.39%	321.32%	547.40%
Revenue Q/Q Growth	91.10%	-79.33%	60.17%	41.27%	-4.31%	140.70%	-28.07%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	87.59%	-132.19%	132.98%	565.13%	-78.63%	198.75%	-512.27%	88.35%	1.81%	-9.22%
EBIT Q/Q Growth	95.35%	-127.50%	128.17%	416.35%	-72.85%	210.82%	-421.90%	87.32%	2.02%	-8.45%
NOPAT Q/Q Growth	72.91%	-129.80%	159.73%	484.80%	-118.50%	341.10%	-181.99%	77.40%	1.38%	-9.98%
Net Income Q/Q Growth	108.06%	-125.50%	134.21%	346.19%	-126.91%	236.77%	-288.49%	72.90%	2.02%	-8.45%
EPS Q/Q Growth	42.86%	-122.58%	127.94%	395.65%	-122.55%	230.77%	-271.43%	73.42%	1.25%	-8.11%
Operating Cash Flow Q/Q Growth	-30.24%	-160.92%	256.09%	-535.91%	83.62%	30.20%	-117.25%	844.94%	0.65%	-52.60%
Free Cash Flow Firm Q/Q Growth	16.96%	-97.63%	24.14%	-176.32%	-10.06%	-10.68%	-11.08%	550.51%	-28.49%	-16.91%
Invested Capital Q/Q Growth	-52.82%	186.43%	31.40%	47.04%	-2.52%	37.06%	6.67%	-664.44%	82.73%	49.75%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%
EBITDA Margin	-6.03%	-92.84%	59.60%	40.97%	8.70%	38.97%	-94.99%	-11.16%	0.00%	0.00%
Operating Margin	-15.69%	-110.67%	56.42%	35.71%	11.72%	32.04%	-89.70%	-22.88%	0.00%	0.00%
EBIT Margin	-1.98%	-81.21%	61.03%	42.84%	11.72%	41.30%	-89.70%	-12.36%	0.00%	0.00%
Profit (Net Income) Margin	3.02%	-71.70%	58.11%	39.74%	-22.81%	81.08%	-142.70%	-26.42%	0.00%	0.00%
Tax Burden Percent	-153.04%	88.30%	95.23%	92.77%	-103.77%	196.32%	214.62%	213.70%	100.00%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	187.50%	100.00%	74.12%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	4.77%	7.23%	203.77%	-96.32%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	19.56%	16.43%	32.80%	9.41%	-2.94%	-9.07%	-35.58%	-31.41%	-37.01%	-49.39%
Cash Return on Invested Capital (CROIC)	-489.22%	-289.92%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-464.48%	0.00%
Operating Return on Assets (OROA)	-0.84%	-33.62%	27.16%	14.15%	4.19%	9.48%	-9.86%	-0.79%	0.00%	0.00%
Return on Assets (ROA)	1.28%	-29.69%	25.86%	13.12%	-8.16%	18.61%	-15.69%	-1.68%	0.00%	0.00%
Return on Common Equity (ROCE)	19.56%	16.43%	32.80%	9.41%	-2.94%	-9.07%	-35.58%	-31.41%	-37.01%	-22.15%
Return on Equity Simple (ROE_SIMPLE)	0.00%	13.01%	24.29%	8.72%	0.00%	-8.83%	-39.81%	-34.68%	0.00%	-37.92%
Net Operating Profit after Tax (NOPAT)	-4.11	-15	51	20	-5.09	28	-11	-4.05	-18	-18
NOPAT Margin	-10.98%	-77.47%	53.72%	33.13%	-12.16%	62.90%	-62.79%	-16.02%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	1.37%	0.30%	0.98%	1.06%	-1.67%	2.79%	-4.68%	-0.78%	-2.85%	-4.13%
Return On Investment Capital (ROIC_SIMPLE)	-0.94%	-	-	-	-2.10%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	26.36%	50.95%	9.75%	15.90%	20.67%	17.22%	44.96%	31.43%	0.00%	0.00%
R&D to Revenue	89.33%	159.72%	33.83%	48.39%	67.60%	50.74%	144.74%	91.46%	0.00%	0.00%
Operating Expenses to Revenue	115.69%	210.67%	43.58%	64.29%	88.28%	67.96%	189.70%	122.88%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-0.74	-16	58	25	4.91	18	-16	-3.12	-25	-25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.25	-18	56	24	3.64	17	-17	-2.82	-24	-25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.51	1.41	1.12	1.77	2.08	0.00	2.43	2.09	2.00	2.12
Price to Tangible Book Value (P/TBV)	1.51	1.41	1.12	1.77	2.08	0.00	2.43	2.09	2.00	2.12
Price to Revenue (P/Rev)	3.07	2.76	2.01	2.92	3.90	0.00	11.57	18.99	0.00	0.00
Price to Earnings (P/E)	9.86	10.50	4.51	18.50	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	10.14%	9.52%	22.16%	5.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	14.44	6.00	0.00	0.00	0.00	0.00	0.00	0.00	7.58	15.80
Enterprise Value to Revenue (EV/Rev)	1.11	0.96	0.05	0.91	1.17	0.00	2.90	2.69	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	3.89	3.99	0.13	4.11	16.62	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	3.53	3.57	0.12	3.67	12.57	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	5.05	4.97	0.13	10.81	86.44	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	1.08	0.00	1.11	0.52	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	1.06	0.00	0.97	0.49	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.02	0.15	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.00
Long-Term Debt to Equity	0.00	0.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.14	-1.11	-1.33	-1.48	-1.17	-1.19	-1.34	-1.33	-0.92	-0.94
Leverage Ratio	1.48	1.55	1.69	1.98	1.59	1.58	1.71	1.56	1.09	1.14
Compound Leverage Factor	1.48	1.55	1.69	1.98	2.97	1.58	1.26	1.56	1.09	1.14
Debt to Total Capital	1.73%	12.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.80%	0.00%
Short-Term Debt to Total Capital	1.73%	1.60%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.80%	0.00%
Long-Term Debt to Total Capital	0.00%	11.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	98.27%	87.33%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	96.20%	100.00%
Debt to EBITDA	0.13	1.18	0.00	0.00	0.00	0.00	0.00	0.00	-0.09	0.00
Net Debt to EBITDA	-6.85	-7.49	0.00	0.00	0.00	0.00	0.00	0.00	1.95	0.00
Long-Term Debt to EBITDA	0.00	1.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.16	1.48	0.00	0.00	0.00	0.00	0.00	0.00	-0.12	0.00
Net Debt to NOPAT	-8.89	-9.34	0.00	0.00	0.00	0.00	0.00	0.00	2.65	0.00
Long-Term Debt to NOPAT	0.00	1.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	4.94	3.52	3.19	1.76	1.60	0.00	1.05	1.35	5.98	6.99
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	55.15%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.15	6.59	5.70	2.38	2.33	2.32	3.10	2.94	9.55	10.89
Quick Ratio	10.64	6.36	5.47	1.88	2.22	2.14	2.99	2.79	8.59	10.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-130	-156	-79	-104	137	152	170	191	-42	-33
Operating Cash Flow to CapEx	-4,977.17%	-3,797.50%	3,808.13%	-3,045.23%	-411.17%	-1,691.44%	-2,305.58%	12,194.18%	-3,856.50%	-3,392.84%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.42	0.41	0.45	0.33	0.36	0.23	0.11	0.06	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	19.06	19.72	21.41	15.97	13.67	9.43	4.62	3.05	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	16	34	-40	-58	-110	-107	-170	-182	32	18
Invested Capital Turnover	-4.52	-5.94	-2.28	-1.36	-3.34	-1.95	-0.55	-0.30	0.00	0.00
Increase / (Decrease) in Invested Capital	126	141	130	124	-142	-125	-182	-196	25	15
Enterprise Value (EV)	235	206	11	149	152	0.00	126	68	244	279
Market Capitalization	647	594	481	476	504	0.00	503	480	425	494
Book Value per Share	$11.46	$11.36	$12.74	$8.02	$7.26	$7.41	$6.23	$6.94	$6.77	$7.43
Tangible Book Value per Share	$11.46	$11.36	$12.74	$8.02	$7.26	$7.41	$6.23	$6.94	$6.77	$7.43
Total Capital	436	484	430	269	242	247	207	230	221	233
Total Debt	7.56	61	0.00	0.00	0.00	0.00	0.00	0.00	8.41	0.00
Total Long-Term Debt	0.00	54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-412	-388	-470	-327	-352	-354	-377	-412	-180	-216
Capital Expenditures (CapEx)	0.64	0.64	1.05	0.84	0.98	1.45	1.52	1.67	0.71	0.81
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-12	-47	-66	-87	-141	-136	-113	-125	7.60	-2.39
Debt-free Net Working Capital (DFNWC)	408	402	404	240	211	218	264	287	196	213
Net Working Capital (NWC)	401	395	404	240	211	218	264	287	188	213
Net Nonoperating Expense (NNE)	-5.24	-1.13	-4.16	-3.91	4.45	-7.95	15	2.63	6.72	6.98
Net Nonoperating Obligations (NNO)	-412	-388	-470	-327	-352	-354	-377	-412	-180	-216
Total Depreciation and Amortization (D&A)	-1.52	-2.28	-1.35	-1.10	-1.26	-1.02	-0.96	0.30	0.42	0.48
Debt-free, Cash-free Net Working Capital to Revenue	-5.64%	-21.78%	-27.58%	-53.53%	-109.29%	-155.99%	-259.12%	-495.21%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	193.62%	186.99%	168.64%	147.50%	163.53%	249.65%	608.46%	1,134.37%	0.00%	0.00%
Net Working Capital to Revenue	190.03%	183.40%	168.64%	147.50%	163.53%	249.65%	608.46%	1,134.37%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.20)	($0.35)	$1.61	$0.70	($0.28)	$1.07	($0.78)	($0.21)	($0.79)	($0.80)
Adjusted Weighted Average Basic Shares Outstanding	37.31M	40.63M	34.18M	33.50M	33.05M	33.28M	33.16M	32.37M	31.29M	31.30M
Adjusted Diluted Earnings per Share	($0.20)	($0.35)	$1.55	$0.68	($0.23)	$1.02	($0.78)	($0.21)	($0.79)	($0.80)
Adjusted Weighted Average Diluted Shares Outstanding	39.00M	40.63M	35.51M	34.79M	33.05M	34.78M	33.16M	32.37M	31.29M	31.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.59M	37.42M	37.20M	33.76M	33.60M	33.37M	33.27M	33.20M	33.08M	31.41M
Normalized Net Operating Profit after Tax (NOPAT)	-4.11	-15	51	20	3.43	9.81	-11	-4.05	-18	-18
Normalized NOPAT Margin	-10.98%	-77.47%	53.72%	33.13%	8.20%	22.43%	-62.79%	-16.02%	0.00%	0.00%
Pre Tax Income Margin	-1.98%	-81.21%	61.03%	42.84%	21.98%	41.30%	-66.49%	-12.36%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Entrada Therapeutics' Financials

When does Entrada Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Entrada Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Entrada Therapeutics' net income changed over the last 2 years?

Entrada Therapeutics' net income appears to be on a downward trend, with a most recent value of $65.63 million in 2024, falling from -$94.62 million in 2022. The previous period was -$6.69 million in 2023. See Entrada Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Entrada Therapeutics's operating income?

Entrada Therapeutics's total operating income in 2024 was $47.01 million, based on the following breakdown:

Total Gross Profit: $210.78 million
Total Operating Expenses: $163.77 million

How has Entrada Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Entrada Therapeutics' total revenue changed from $0.00 in 2022 to $210.78 million in 2024, a change of 21,078,200,000.0%.

How much debt does Entrada Therapeutics have?

Entrada Therapeutics' total liabilities were at $97.64 million at the end of 2024, a 57.0% decrease from 2023, and a 147.2% increase since 2022.

How much cash does Entrada Therapeutics have?

In the past 2 years, Entrada Therapeutics' cash and equivalents has ranged from $45.16 million in 2022 to $101.21 million in 2024, and is currently $101.21 million as of their latest financial filing in 2024.

How has Entrada Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Entrada Therapeutics' book value per share changed from 6.77 in 2022 to 11.46 in 2024, a change of 69.3%.

Related Companies

This page (NASDAQ:TRDA) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Financials

Frequently Asked Questions About Entrada Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Financials

Annual Income Statements for Entrada Therapeutics

Quarterly Income Statements for Entrada Therapeutics

Annual Cash Flow Statements for Entrada Therapeutics

Quarterly Cash Flow Statements for Entrada Therapeutics

Annual Balance Sheets for Entrada Therapeutics

Quarterly Balance Sheets for Entrada Therapeutics

Annual Metrics And Ratios for Entrada Therapeutics

Quarterly Metrics And Ratios for Entrada Therapeutics

Frequently Asked Questions About Entrada Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools